Investors bought shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) on weakness during trading hours on Thursday. $49.17 million flowed into the stock on the tick-up and $35.90 million flowed out of the stock on the tick-down, for a money net flow of $13.27 million into the stock. Of all equities tracked, Zimmer Biomet had the 28th highest net in-flow for the day. Zimmer Biomet traded down ($0.24) for the day and closed at $122.29
A number of brokerages have recently issued reports on ZBH. Jefferies Group reaffirmed a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet in a research report on Friday, November 3rd. Stifel Nicolaus reissued a “hold” rating and set a $120.00 price objective on shares of Zimmer Biomet in a report on Friday, November 3rd. SunTrust Banks reissued a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet in a report on Monday, October 2nd. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a report on Friday, November 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zimmer Biomet in a report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet currently has a consensus rating of “Buy” and a consensus price target of $137.42.
The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. The stock has a market cap of $24,760.00, a price-to-earnings ratio of 38.10, a P/E/G ratio of 1.96 and a beta of 1.15.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s payout ratio is 29.91%.
A number of large investors have recently bought and sold shares of ZBH. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in Zimmer Biomet by 99.6% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 9,942 shares of the medical equipment provider’s stock valued at $1,277,000 after purchasing an additional 4,960 shares during the last quarter. Schroder Investment Management Group purchased a new stake in Zimmer Biomet in the second quarter valued at $4,783,000. CIBC World Markets Inc. purchased a new stake in Zimmer Biomet in the second quarter valued at $270,000. Aberdeen Asset Management PLC UK boosted its holdings in Zimmer Biomet by 6.7% in the second quarter. Aberdeen Asset Management PLC UK now owns 47,505 shares of the medical equipment provider’s stock valued at $6,099,000 after purchasing an additional 2,995 shares during the last quarter. Finally, Financial Counselors Inc. boosted its holdings in Zimmer Biomet by 1.2% in the second quarter. Financial Counselors Inc. now owns 6,215 shares of the medical equipment provider’s stock valued at $798,000 after purchasing an additional 73 shares during the last quarter. 85.92% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Traders Buy Shares of Zimmer Biomet (ZBH) on Weakness” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2018/01/11/traders-buy-shares-of-zimmer-biomet-zbh-on-weakness.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.